| abstract |
Disclosed herein are compounds that form a covalent bond with Breton tyrosine kinase (BTK). Similarly, irreversible inhibitors of Btk are also described. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions containing the compounds. Disclosed are methods of using a Btk inhibitor alone or in combination with other therapeutic agents for treating autoimmune diseases or conditions, including lymphoma and inflammatory diseases or conditions, heterogeneous immune diseases or conditions, cancer. [Selection figure] None |